In the context of breast cancer, it has been shown that O-GlcNAcylation-increasing treatments reduce estrogen receptor α (ERα) expression and protect MCF-7 cells from death induced by tamoxifen, a chemical largely used as a partial antagonist of the estrogen receptor in ER positive breast cancers [167]. The gene discussed is ESR1; the disease is breast carcinoma.